Abstract
Objective: To investigate the predictive value of elevated serum S100B level in patients with multiple traumas combined delirium for the clinical prognosis prior to intensive care unit (ICU) discharge. Methods: One hundred seventy-nine patients with multiple traumas diagnosed as delirium after admission over 48 hours to the Department of Critical Care Medicine, People's Hospital Affiliated to Jiangsu University from January 2013 to December 2016 were divided into two groups according to the level of serum S100B measured prior to the ICU discharge: high S100B group (≥0.20 μg/L, n=53) and low S100B group (<0.20 μg/L, n=126). The difference of the clinical prognoses between the two groups was evaluated with t or Chi-square test. Results: The patients in high S100B group had a higher ICU readmission rate (18.9% vs 6.3%, χ(2)=6.464, P=0.011). The 30-day mortality was higher for patients in high S100B group than that in low S100B group (5.7% vs 4.0%, χ(2)=0.308, P=0.579). The incidence of adverse outcome was also significantly higher for patients in high S100B group than that in low S100B group (35.8% vs 17.5%, χ(2)=7.144, P=0.008). The sequential organ failure assessment (SOFA) score before ICU discharge was also higher for patients in the high S100B group than that in the low S100B group (3.2±1.3 vs 2.4±1.1, t=4.204, P=0.000). The duration of ICU stay for patients in high S100B group was significantly longer than that in the low S100B group[(16±8) vs (12±5) d, t=4.095, P=0.000]. The area under the curve (AUC) of receiver operating characteristics of the S100B was 0.742, 95% CI: 0.574-0.910. The multivariate logistic regression analysis revealed that the odds ratio (95% CI) in the prediction of adverse outcomes by S100B level prior to the ICU discharge was 1.39(1.15-1.53), P=0.009. Conclusion: Elevated serum level of S100B in patients with multiple traumas combined delirium prior to ICU discharge is closely associated with poor clinical prognosis, but it is only a modest predictor that may not be used alone in judgements of clinical treatments for patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.